Neurologix is a clinical-stage biotechnology company engaged in discovery, development and commercialization of life-altering gene transfer therapies for serious disorders of the brain and central nervous system.
The company’s loss from operations was $2.06m, compared to $3.14m for the same period last year.
Neurologix president and CEO Clark Johnson said they are continuing on the path to develop NLX-P101, their Parkinson’s disease gene transfer therapy, as a much needed therapy for patients with Parkinson’s disease and plan to submit a Phase 3 protocol to the FDA later this year.